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    Key messages
▶  OTC products such as energy 
drinks or dextrose are the pre-
parations most commonly used 
with the aim of boosting mental 
performance.
▶  About 1.8 % of women and 1.3 % 
of men take medicines or illegal 
substances that can be used to 
enhance mental performance.
▶  These agents are used mainly 
by 18- to 44-year-old women 
and men.
▶  A long working week increases 
people's risk of using medicines 
or illegal substances to enhance 
their mental performance.
Pharmacological Neuroenhancement 
The consumption of substances that affect a person's waking state and mental 
performance is not a new social phenomenon. Since time immemorial, people 
have tried to improve not only their physical performance but also their mental 
capacity by using drugs, substances or preparations. The consumption of coffee 
and alcohol, to name just two examples, has always been widespread and largely 
accepted by society. However, the development of psychostimulants – such as 
amphetamines in the 1930s, antidepressants in the 1950s, or modafinil and 
anti-dementia agents in the 1990s (Franke, Lieb 2010) – opened up new ways of 
influencing mental performance. 
Substances that can be used to boost mental performance are known as neu-
roenhancers. When healthy people use neuroenhancers, they usually have one 
of two aims in view: either to boost such intellectual skills as learning, memory, 
mental attentiveness and vigilance (alertness), or to improve functional social 
skills by improving their mood, avoiding stress and nervousness, and reducing 
social anxiety (Norman et al. 2010).
However, most drugs that can be used for neuroenhancement only have a 
limited benefit. Some agents only make people more alert and improve their 
concentration and attentiveness for a short time – if at all – and do not seem to 
directly improve a person's memory. In particular, anti-depressants and anti-
dementia agents do not have any verifiable effect on healthy people. Apart from 
which, there is a risk of undesirable side effects, for example mental disorders 
and addictions (Franke, Lieb 2010). Apart from the possible side effects, the abuse 
of prescription drugs also raises legal issues.
Since the results of a study commissioned by the science magazine Nature 
were published in 2008, the use of neuroenhancers has been the subject of much 
discussion in the international scientific community and especially in the media. 
In this study, 1,400 readers were interviewed on the subject of brain doping (see 
box). About 20 % of the respondents from 60 countries stated that they had taken 
drugs to enhance their concentration and memory without medical reasons; 62 % 
had taken methylphenidate, 44 % modafinil and 15 % beta blockers (Maher 2008).
In Germany, the 2009 Health Report of the Deutsche Angestellten Kran-
kenkasse (DAK, a health insurance fund) took up the theme of »doping at the 
workplace« and conducted both a survey of experts and an online survey of 3,000 
people insured by the DAK. The experts suspected »that drug use seems to be a 
socially accepted form of behaviour in everyday life and at work for coping with 
pain, discomfort, work pressure, stress, etc.« (DAK 2009, page 84). The evalu-
ation of the online survey, however, showed that about 5 % of people in regular 
employment between the ages of 20 and 50 took brain-doping agents without 
medical necessity. 
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The DAK study focused exclusively on prescription 
psychostimulants (methylphenidate, modafinil), agents 
against dementia (e. g. donepezil) and depression (e. g. 
fluoxetine), and beta blockers. Other studies, by contrast, 
do not restrict themselves to the use of prescription neu-
roenhancement drugs, but also include over-the-counter 
(OTC) substances, such as ginkgo biloba, and illegal psy-
chostimulants such as amphetamines, cocaine and ecstasy 
(Teter et al. 2006. Maher 2008; Franke et al. 2009 ). 
Study on the consumption of performance-enhancing 
substances (KOLIBRI)
A Germany-wide survey of 6,142 people was conducted 
in 2010 on the consumption of performance-enhancing 
substances in everyday life and leisure time as part of the 
Robert Koch Institute's KOLIBRI study. It covered the use 
of prescription and illegal substances (e. g. amphetamines), 
as well as OTC products, by the general population over 18 
years. These data enable representative conclusions to be 
drawn on the use of substances for pharmacological neu-
roenhancement by the adult population in Germany. The 
analysis is based on the use of such agents – not to treat an 
illness – at least once during the last twelve months. The 
choice of neuroenhancement agents is modelled on those 
chosen in the DAK study and include prescription psycho-
stimulants (methylphenidate, modafinil), anti-dementia and 
anti-depression agents, and beta blockers. Both fluoxetine 
and St. John's wort were listed as examples in the same res-
ponse category in the group of antidepressants. Fluoxetine, 
and some preparations containing St. John's wort used to 
treat mild or moderate depression, require a prescription; 
however, most St. John's wort products are available without 
a prescription. Illegal substances, such as amphetamines, 
were also taken into account. 
The above set of preparations is referred to in the fol-
lowing as »medicines or illegal substances for neuroen-
hancement«.
Use is not widespread
In the KOLIBRI study a total of 74 respondents said they 
had used medicines or illegal substances for neuroenhan-
cement at least once during the last twelve months. This 
corresponded to a 12-month prevalence among adults in 
Germany of 1.5 %. The prevalence rates for men and women 
were approximately at the same level (Table 1). 
The use of antidepressants without medical necessity 
was reported most often by both women and men. The 
second most frequently consumed substances were syn-
thetic chemical stimulants such as amphetamines. Beta 
blockers were used by only 0.1 % (n = 6) without medical 
necessity. Antidepressants were more likely to be used 
by women. The use of methylphenidate or anti-dementia 
agents was measured in tenths of a percent among women. 
Only one respondent reported using each type. Modafinil 
was not used by any participant without medical necessity.
Preparations are used mainly by younger people
The percentage of women and men who use medicines or 
illegal substances for neuroenhancement tends to fall as they 
grow older (Figure 1). Just under 3 % of women and men 
between the ages of 18 and 44 used such substances without 
medical necessity, compared to only 0.7 % of women and 
men over 45. Women between the ages of 30 and 44 used 
medicines or illegal substances for neuroenhancement most 
frequently: 3.7 %. Among men, the use of these products was 
most widespread in the 18-to-29 age group; the figure here 
was 3.3 %. 
Odds ratios (OR) with corresponding 95 % confidence 
intervals (CI) were calculated as a measure of the correla-
tion between people's age and their use of medicines or 
illegal substances for neuroenhancement. According to 
this measure, the risk of younger adults (aged 18 to 44) 
using these agents without medical necessity was more 
Study on the consumption of performance- 
enhancing substances in everyday life and leisure 
time (KOLIBRI) 
Data holder: Robert Koch Institute
Objectives:  To provide data on the prevalence 
of the use of performance-enhan-
cing substances in the general 
populationg
Survey method:  Population-based, written, postal 
survey 
Population:  Residential population of Germany 
aged 18 and over 
Sample:  6,142 women and men who agreed 
in the GEDA 2009 and 2010 surveys 
to take part in a further survey
Response rate:  62.2 % 
Survey period:  March to July 2010
Definition pharmacological neuroenhancement
The use of psychoactive substances of all kinds to boost men-
tal or cognitive performance is subsumed under the term 
pharmacological neuroenhancement.
The term brain doping is also frequently used in this context. 
According to a definition given by Franke and Lieb (2010), this 
term relates to doping in sport and refers exclusively to the 
improper use of psychoactive substances and preparations 
that are either subject to prescription or illegal. They inclu-
de psycho- and neurotropic drugs that have been approved 
for treating dementia, attention-deficit or sleep disorders and 
depression, as well as beta blockers and synthetic chemical 
stimulants such as amphetamine (Franke, Lieb 2010).
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In women, the difference between the employment 
groups regarding the use of medicines or illegal substan-
ces for neuroenhancement was lower overall. Approxi-
mately 3.1 % of women with a working week of more than 
40 hours used medicines or illegal neuroenhancers. The 
figure was 1.7 % among women who were not employed or 
worked less than 20 hours. 
Statistical confirmation of the results using logis-
tic regression analyses shows, when controlling for the 
influence of age, that the differences according to weekly 
employment are only statistically significant among men. 
According to this, the risk of men with a working week of 
more than 40 hours using preparations to enhance their 
mental and social skills (OR 3.0; 95 % CI 1.2 to 7.7) is three 
times that of men of the same age who are not employed 
or work less than 40 hours. 
OTC products are most commonly used 
In addition to medicines and illegal substances, KOLIBRI 
also covered OTC (over-the-counter) products that can be 
used for neuroenhancement (e. g. energy drinks). Respon-
dents were summarily asked about possible motivations for 
using all of these substances if they reported using at least 
one of them without medical necessity. In addition to physi-
cally oriented motives, one option was »to improve or enhan-
ce mental performance (e. g. concentration)«. 
Overall, 16.9 % of the men and 12.8 % of the women 
used substances with the aim of enhancing their mental 
performance. This meant that men used such substances 
significantly more frequently than women with this aim 
in view. 
However, the majority of people who gave this motive 
were using OTC products like dextrose, energy drinks or 
isotonic drinks. Medicines such as antidepressants, anti-
dementia agents, modafinil, methylphenidate and beta 
blockers, or illegal substances such as synthetic chemical 
than four times higher than those aged 45 and over (OR 
4.3; 95 % CI 2.2 to 9.1). This was observed in both women 
(OR 4.2; 95 % CI 1.6 to 11.3) and men (OR 5.1; 95 % CI 2.0 
to 12.9). Statistical control of the influence of age did not 
reveal any significant influence of educational attainment 
on the use of medicines or illegal substances for neuroen-
hancement either in women or in men. 
A long working week increases the risk of  
using neuroenhancement 
The data of the KOLIBRI study show that the use of medi-
cines or illegal substances that can be used to improve 
cognitive or social skills is related to employment (Figure 
2). About 2.6 % of men who worked more than 40 hours 
a week used medicines or illegal substances for neuro-
enhancement without medical necessity. By contrast, the 
figure was 0.7 % among men who were not employed or 
worked less than 40 hours. 
Table 1
Use of medicines without medical necessity and illegal substances for neuroenhancement during the last 12 months
Data basis: KOLIBRI 2010
Women Men Total
% (95 % CI) % (95 % CI) % (95 % CI)
Beta blockers 0.1 (0.0 – 0.2) 0.0 (0.0 – 0.1) 0.1 (0.0 – 0.1)
Synthetic chemical stimulants 0.5 (0.2 – 1.3) 0.5 (0.2 – 1.1) 0.5 (0.3 – 1.0)
Methylphenidate 0.0 (0.0 – 0.2) n. a. n. a. 0.0 (0.0 – 0.1)
Anti-dementiva agents 0.0 (0.0 – 0.1) n. a. n. a. 0.0 (0.0 – 0.1)
Antidepressants 1.2 (0.7 – 2.0) 0.7 (0.4 – 1.3) 1.0 (0.7 – 1.4)
Modafinil n. a. n. a. n. a. n. a. n. a. n. a.
Total 1.8 (1.2 – 2.8) 1.3 (0.8 – 2.0) 1.5 (1.1 – 2.1)
Figure 1
Use of medicines or illegal substances for neuroenhancement in the last 12 
months, by age and gender 
Data basis: KOLIBRI 2010
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Discussion
No population-level data on pharmacological neuroen-
hancement have been available up to now, but these have 
now been presented with the KOLIBRI study (please go to: 
www.rki.de for a report [in German]). The results of the 
KOLIBRI study show that pharmacological neuroenhan-
cement with medicines or illegal substances is not wides-
pread in Germany's adult general population. About 1.8 % 
of women and 1.3 % of men used drugs without medical 
necessity or illegal substances for neuroenhancement. 
There was nevertheless a willingness among young adults 
to increase their mental performance by consuming subs-
tances. However, it was primarily OTC products that were 
used to enhance mental performance. 
To date, information on the use of prescription or illegal 
psychostimulants – such as methylphenidate, amphetami-
nes, cocaine or ecstasy – for neuroenhancement in Germa-
ny is only available relating to students of senior secondary 
schools and vocational schools in small towns and large 
cities, as well as for university students of medicine, phar-
macy and economics (Franke et al. 2009; Middendorf et 
al. 2012). 
The study's findings on school and university students 
on the use of prescription and illegal psychostimulants 
show that 1.5 % of school students and 0.8 % of university 
students have ever used prescription psychostimulants 
(methylphenidate) (Franke et al. 2009). The lifetime pre-
valences of illegal neuroenhancers (amphetamines, coca-
ine, ecstasy) – 2.4 % for school students and 2.9 % for 
university students – are higher than those for the use of 
prescription neuroenhancers.
In addition, an online survey on »academic brain 
doping« conducted among 8,000 students by the HIS-
stimulants, were only used by a very small number of 
women and men with this motivation (Figure 3). Antide-
pressants accounted for the largest share here. 
Better mental performance is a motive, especially 
among younger people 
The motivation for using substances to improve or 
enhance their mental performance was markedly more 
pronounced in young adults between 18 and 29 than in 
the older age groups. Approximately 42.8 % of consu-
ming men and 37.4 % of the women between 18 and 29 
stated this motivation, compared to less than 10 % in the 
45-to-64 age group and less than 5 % among the over-65s 
(Figure 4 ).
Figure 3
Use of performance-enhancing substances by people who said their motivation was »to improve or 
enhance mental performance«, by product group
Databasis: KOLIBRI 2010
Figure 2
Use of medicines or illegal substances for neuroenhancement, by length of 
working week and by gender
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Addiction shows a high degree of correlation. The latter 
reported a prevalence of 0.8 % for the use of amphetami-
nes in the last twelve months among 18- to 59-year-olds 
and of 4.5 % for antidepressants in the 18-to-64 age group 
(Kraus et al. 2010a; 2010b). The directly comparable pre-
valences for amphetamines in KOLIBRI – i. e. irrespective 
of whether they were used to treat one or more disea-
ses – are 0.9 % for 18- to 59-year-olds and 3 % for antide-
pressants among 18- to 64-year-olds. Differences between 
women and men as regards frequency of use are similar 
for all compared substances. It should be noted that the 
level of frequencies determined essentially depends on 
the composition of the set of agents for neuroenhance-
ment or the population group studied. 
Nevertheless, the above-mentioned studies show simi-
lar prevalences of neuroenhancement or brain doping in 
the populations examined. However, there is a suspicion 
that, in the case of survey studies on the use of illegal 
substances or prescription drugs without medical neces-
sity, social desirability plays a major role and influences 
the answers to the questions. As a result, it can be assu-
med that the reported prevalences underestimate the true 
extent of the use of brain-doping substances. 
In the light of the study data described here, there is 
currently no scientific evidence to suggest that a large 
number of people in Germany practise brain doping. 
Summing up, the authors of the 2009 DAK Health 
Report say that, taken as a whole, the survey results do 
not support »the assumption that doping at the work-
place or enhancement by active employees is (already) 
a widespread phenomenon. Rather, there is a growing 
impression that a distorted picture is being presented to 
the public« (DAK 2009, p.60). 
The conclusion that the use of prescription psycho- 
and neuropharmaceuticals without medical necessity is 
not widespread in the population is corroborated by the 
results of the KOLIBRI study, although the latter indicate 
that, despite the low prevalences for the use of brain-
doping agents, there is definitely a willingness among 
parts of the adult population to resort to performance-
enhancing substances to improve mental performance. 
In general, however, prescription or illegal substan-
ces are not used, but primarily OTC and therefore easily 
accessible products. However, the risks associated with 
the frequent use of these agents have hardly been studied 
up to now. In light of the findings presented, it seems 
advisable to address the indiscriminate use of pharma-
cological neuroenhancers, to educate people about the 
consequences of using these substances, and to encou-
rage health-related behaviour that enables people to live 
without consuming such agents. 
Furthermore, the results of the KOLIBRI study and 
other studies refer to the connection between neuroen-
hancement and (psychosocial) workloads. However, the 
data provide no information on whether such substances 
really are used to compensate for such stress, or, if so, 
Institute for Research on Higher Education in Decem-
ber 2010 showed that 5 % of the respondents resorted to 
prescription drugs or illegal substances to enable them to 
cope with their studies better. 18 % of these took methyl-
phenidate, 12 % beta blockers, 9 % amphetamines and 
4 % modafinil. In addition to the psycho- and neurophar-
maceuticals included in KOLIBRI, the HIS study also 
included the consumption of painkillers, barbiturates 
and sedatives, as well as cannabis, cocaine and MDMA 
(ecstasy's active ingredient) in the analysis. While just 
under half used such agents »very rarely«, 17 % did so 
»frequently« and a further 36 % »now and then« (Mid-
dendorf et al. 2012).
In the online survey conducted as part of the DAK's 
2009 Health Report (DAK 2009), in which about 3,000 
people in regular employment aged between 20 and 50 
were interviewed, 17 % of the respondents reported that 
they had taken medicines to improve their mental perfor-
mance or psychological well-being; 5 % of the respondents 
used these drugs without medical necessity. 2 % used neu-
ro- or psychotropic drugs frequently and/or regularly wit-
hout a doctor's prescription. 
Although a certain amount of information on the use of 
medicines or illegal drugs for pharmacological neuroen-
hancement can be obtained by from secondary analyses of 
data from the 2009 Drug Report of the GEK (Gmündener 
Ersatzkasse, a health insurance fund) (Glaeske, Schick-
tanz 2010), the 2009 Epidemiological Survey on Addic-
tion (Kraus et al. 2010a) and the 1998 Federal Health 
Survey on drug use (RKI 2003), this information sheds 
little light on the distribution of a set of agents for neuro-
enhancement that contain both components. Moreover, 
the reported prevalences were based on different periods. 
A comparison of the 12-month prevalences for the use of 
amphetamines or antidepressants in the KOLIBRI study 
with the results of the 2009 Epidemiological Survey on 
Figure 4
Percentage of people who consumed in the last 12 months and said their 
motivation was »to improve or enhance mental performance (e.g. concent-
ration)«, by age and gender
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which occupations are affected. Further research is there-
fore needed before any reliable conclusions can be drawn 
on the connection between pharmacological neuroenhan-
cement and workloads.
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